G1 Therapeutics (NASDAQ:GTHX) posted its earnings results on Tuesday. The company reported ($0.86) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.01, Fidelity Earnings reports.
GTHX traded up $0.20 during trading on Friday, hitting $23.68. The stock had a trading volume of 223,327 shares, compared to its average volume of 399,541. The company has a 50 day moving average price of $24.76 and a 200-day moving average price of $26.40. The firm has a market cap of $839.76 million, a price-to-earnings ratio of -9.25 and a beta of 2.21. G1 Therapeutics has a one year low of $13.87 and a one year high of $46.50.
GTHX has been the topic of a number of recent analyst reports. Cowen reissued a “buy” rating on shares of G1 Therapeutics in a report on Wednesday. BidaskClub lowered G1 Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, September 17th. B. Riley set a $55.00 target price on G1 Therapeutics and gave the stock a “buy” rating in a report on Friday, September 27th. ValuEngine upgraded G1 Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Finally, Zacks Investment Research upgraded G1 Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 2nd. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. G1 Therapeutics currently has an average rating of “Buy” and an average target price of $56.67.
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial.
Read More: What is meant by holder of record?
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.